ZK 283197

Drug Profile

ZK 283197

Alternative Names: BAY86-5310; SH T04211C

Latest Information Update: 18 Feb 2014

Price : $50

At a glance

  • Originator Bayer HealthCare
  • Class
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Vasomotor symptoms

Most Recent Events

  • 18 Feb 2014 Discontinued - Phase-II for Vasomotor symptoms in United Kingdom, Germany & Netherlands (PO)
  • 31 Dec 2008 Bayer completes a phase II trial in Vasomotor symptoms in United Kingdom, Germany & Netherlands (NCT00537836)
  • 31 Oct 2007 Phase-II clinical trials in Vasomotor symptoms in United Kingdom, Germany & Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top